December 2nd 2024
If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
New pediatric therapies emerging
April 1st 2004Washington -- New therapies continue to emerge in pediatric dermatology, and recent studies demonstrate the effectiveness of such therapies. Ilona J. Frieden, M.D., highlighted studies in some areas of common concern in a presentation at the annual meeting of the American Academy of Dermatology.
Newer May Not Always Be Better
April 1st 2004About 15 years ago, while riding on a shuttle bus at the annual American Academy of Dermatology meeting, I overheard two elderly dermatologists discussing the state of dermatology, as they perceived it. One gentleman commented that he had not seen a single advance to rival the advent of tetracycline for acne, and that most of the new treatments did not work very well. At the time, I remember thinking that these practitioners were out of touch with all of the hot new therapies for skin disorders. Since that time, as I have been bombarded by myriad new and supposedly revolutionary "advances," I, too, am beginning to question whether we should equate the concept of "newness"
Neonatal lupus raises more issues
April 1st 2004Washington - Cutaneous lesions are common in infants with neonatal lupus erythematosus (NLE) and may have life-long sequelae. However, the most worrisome associations are its noncutaneous features and the increased risks for a mother to develop an autoimmune disorder herself, said Amy S. Paller, M.D., at the annual meeting of the American Academy of Dermatology.
Contact dermatitis from topicals tops list of adverse drug reactions
April 1st 2004Boca Raton, Fla. - Contact dermatitis from topical medications is the most common type of adverse drug reaction, and allergic contact dermatitis is the most common and most important form of contact dermatitis induced by topical drugs, according to James S. Taylor, M.D., head of the industrial dermatology section of the department of dermatology at the Cleveland Clinic Foundation in Cleveland. "Patients with medicament contact dermatitis usually have a good prognosis, but with a propensity for relapse," Dr. Taylor said.
Ancient 'cure' finds believers in the 'burbs
April 1st 2004Maui, Hawaii - For thousands of years, people have flocked to the Dead Sea searching for relief for their itchy skin. Now, Chicago-area psoriasis and atopic dermatitis sufferers are bathing in reconstituted Dead Sea water at a suburban clinic.
Hypnosis: A therapeutic alternative
April 1st 2004Tampa, Fla. -- Dermatologists can use hypnosis as an adjunctive or monotherapy for helping patients relax for in-office procedures, feel less pain, or even change habits such as skin picking. What dermatologists might not know about medical hypnosis is it usually takes only one to three minutes to induce hypnosis, using a brief hypnotic technique, according to Philip D. Shenefelt, M.D., associate professor of medicine, Division of Dermatology in the Department of Internal Medicine, University of South Florida, Tampa.
Resolving Ringworm's Anger: Oral Therapy Remains Key
March 15th 2004PARTICIPANTSMarcia Glynn, MD Assistant Professor, Dermatology Director, PediatricDermatology Martin Luther King/Charles R. Drew Medical Center Los Angeles,CaliforniaJudy Hunter, MD Pediatrician Principal Investigator HealthCare PartnersMedical Group Torrance, California
Unlikely presentation masks case of early juvenile xanthogranuloma
March 1st 2004Washington D.C. - Juvenile Xanthogranuloma (JXG) is a rare histiocytic proliferation of uncertain histogenesis usually found in the cephalic region and more common in males less than one year of age. So when an 11-day old female neonate presented to Wake Forest University Baptist Medical center with a firm, immobile, non-pulsatile, pink-red nodule and telangiectases localized to the right groin, JXG was not initially suspected. However, as part of the initial workup, a confirmatory biopsy revealed the diagnosis.
Stem cells proliferate, regenerate
March 1st 2004National report -- In a study that could have implications for faster wound healing in the future, Australian researchers have dispelled the belief that only epidermal stem cells are capable of tissue regeneration; short term and long term. They report in the February 2004 issue of The Journal of Clinical Investigation that significant proliferative and tissue-regenerative capacity resides in the more mature progeny of keratinocyte stem cells - including early differentiating cells.
Neonatal skin conditions challenge pediatricians
March 1st 2004Miami, Fla. - The challenge in neonatal dermatology is that pediatricians who commonly see various skin conditions in infants often lack the training and knowledge to respond to the skin eruptions, according to the head of pediatric dermatology at the Phoenix Children's Hospital.
New study focuses on treatment, resources, and impact of atopic dermatitis
March 1st 2004Washington -- A recent prospective study has shown that treatment of atopic dermatitis with tacrolimus ointment (Protopic, Fujisawa) produced clinical improvement and reduced healthcare resource use and improved patient and caregiver quality of life, said Mark Boguniewicz, M.D., professor, division of pediatric allergy-immunology, National Jewish Medical and Research Center, Denver, and University of Colorado School of Medicine.
Topical bexarotene benefits mycosis fungoides
March 1st 2004Waikoloa, Hawaii - Bexarotene 1 percent gel (Targretin) is a useful alternative modality, offering advantages to other therapies, for the treatment of mycosis fungoides (MF), according to Joan Guitart, M.D., at the annual Hawaii Dermatology Seminar in January.
Betamethasone valerate effective for short-term stasis dermatitis
March 1st 2004Waikoloa, Hawaii -- Pilot study results indicate that 0.12 percent betamethasone valerate foam is more effective than vehicle alone for short-term stasis dermatitis treatment. "This topical therapy can lead to improved health-related quality of life in these patients," said Alexa Boer Kimball, M.D., assistant professor and director, dermatology clinical trials, Stanford University School of Medicine.
Side effects come to the fore in pediatric dermatology
March 1st 2004Washington, D.C. - Because all the ramifications of new medications - and even some of the older ones - are not yet known, practitioners should give special consideration to possible side effects. In making treatment decisions, get as much information as possible, said Roselyn E. Epps, M.D.